TM-233

• UNSPSC Description:

  TM-233 is an inhibitor of the JAK/STAT and NF-κB signaling pathways, exhibiting significant antitumor activity. TM-233 reduces the expression of the anti-apoptotic protein Mcl-1 by inhibiting the phosphorylation of JAK2 and STAT3, and regulates its transcription by directly binding to the Mcl-1 gene promoter. Additionally, TM-233 prevents the translocation of NF-κB from the cytoplasm to the nucleus by inhibiting its DNA-binding activity, thereby reducing nuclear NF-κB expression. TM-233 shows potential in overcoming Bortezomib (HY-10227) resistance and can be applied in research related to multiple myeloma[1].

• Target Antigen:

  Bcl-2 Family; JAK; NF-κB; STAT

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Epigenetics;JAK/STAT Signaling;NF-κB;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tm-233.html

• Smiles:

  CC(OC(C1=CC=C(C=C1)OC(C)=O)C2=C3C=CC=CC3=CC4=CC=CC=C24)=O

• Molecular Weight:

  384.42

• References & Citations:

  [1]Sagawa M, et al. TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways[J]. Blood, 2013, 122(21): 4427.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1103745-28-3